Rocket Pharmaceuticals And REGENXBIO Announce New License Agreement For The Treatment Of Danon Disease Using NAV AAV9 Vector; REGENXBIO Grants Rocket Exclusive Worldwide Rights To NAV AAV9 And In Return Will Receive $7M Upfront Payment
Benzinga Newsdesk